Capturing Continuous Glucose Monitoring Advantages

Jun 28, 2017

Register Free:

With increasing pricing pressures in a therapeutic area which has seen many recent drug approvals, diabetes drug developers are seeking to enhance their clinical development and portfolio. By leveraging Continuous Glucose Monitoring (CGM), sponsors conducting trails in diabetes as well as other indications have the potential to enhance patient safety, accelerate clinical development and increase commercial value.

Attend this live webinar to hear QuintilesIMS, in collaboration with key CGM opinion leaders, discuss the advantages of using CGM in your clinical trials.

Register for this webinar to learn:

  • Expert insights from QuintilesIMS’s Diabetes Center of Excellence
  • Firsthand case studies on how using CGM devices can help increase commercial value
  • Opportunities for CGM to accelerate clinical trials

Register today to understand how CGM captures near real-time glycemic data that can help enhance patient safety, accelerate clinical development and increase commercial value.

With access to real-time overnight glucose profiles or postprandial hyperglycemia readings, could you make faster, better study decisions? Would your patients be safer? Could this data lead to differentiated claims? By leveraging continuous glucose monitoring (CGM) in combination with operational excellence and therapeutic expertise, QuintilesIMS can help you achieve these results. In collaboration with key CGM opinion leaders, QuintilesIMS offers a free webinar on how utilizing CGM can take your diabetes product to the next level. 


Erica Caveney, MD, Vice President, Global Head, Diabetes Center of Excellence, QuintilesIMS

James R. Johnson, PhD, Principle Biostatistician and Pharmacokineticist, Summit Analytical

Poul Strange, MD, PhD, President and Medical Director, Integrated Medical Development


Date and Time: Wednesday, 28 June 2017 | 11:00 am EDT | 10:00 am CDT | 8:00 am PDT

After the final airing of the webcast 28 June 2017 it will be available on demand until 28 June 2018. 

Register Free:

lorem ipsum